Study Standards. Institution and Investigator shall perform the Study in accordance with (i) the terms and conditions of this Agreement; (ii) the Protocol; (iii) Idorsia's reasonable written instructions (iv) generally accepted standards of good clinical practice; (v) the International Council on Harmonization of Technical Requirements of Pharmaceuticals for Human Use Guideline for Good Clinical Practice (“ICH-GCP”); and (vi) all national and international laws, ordinances, rules, and regulations of any governmental authority ("Regulatory Authority") and any other authority that apply to the conduct of the Study or the activities contemplated hereunder ("Applicable Law"). 1.1
Study Standards. Institution and Investigator shall perform the Study in accordance with (i) the terms and conditions of this Agreement; (ii) the Protocol; (iii) Idorsia's reasonable writ- ten instructions (iv) generally accepted stand- ards of good clinical practice; (v) the Interna- tional Council on Harmonization of Technical Requirements of Pharmaceuticals for Human Use Guideline for Good Clinical Practice (“ICH-GCP”); and (vi) all national and interna- tional laws, ordinances, rules, and regula- tions of any governmental authority ("Regu- latory Authority") and any other authority that apply to the conduct of the Study or the activities contemplated hereunder ("Appli- cable Law"). 1.1
Study Standards. Institution and Investigator shall perform the Study in accordance with (i) the terms and conditions of this Agreement; (ii) the Protocol; (iii) Idorsia's reasonable writ- ten instructions (iv) generally accepted 1.1
Study Standards. The Services will be provided according to the options selected and communicated by you (e.g. _Your Test Item Data).
Study Standards. Institution and Investigator shall perform the Study in accordance with (i) the terms and conditions of this Agreement; (ii) the Protocol; (iii) Idorsia's reasonable writ- ten instructions (iv) generally accepted stand- ards of good clinical practice; (v) the Interna- tional Council on Harmonization of Technical Requirements of Pharmaceuticals for Human Use Guideline for Good Clinical Practice (“ICH-GCP”); and (vi) all national and interna- tional laws, ordinances, rules, and regula- tions of any governmental authority ("Regu- latory Authority") and any other authority 1.1 Standardy Klinického hodnocení. Zdravot- nické zařízení a Zkoušející provádějí Klinické hodnocení v souladu s (i) podmínkami této Smlouvy; (ii) Protokolem; (iii) odůvodněnými písemnými pokyny společnosti Idorsia; (iv) všeobecně přijímanými standardy správné klinické praxe; (v) směrnicí pro správnou klin- ickou praxi International Council on Harmoni- zation of Technical Requirements of Pharma- ceuticals for Human Use Guideline for Good Clinical Practice (xxxx označovaná xxx xxxx „ICH-GCP“); a (vi) veškerými národními a mezinárodními právními předpisy, that apply to the conduct of the Study or the vyhláškami, pravidly a směrnicemi jakéhokoli activities contemplated hereunder ("Appli- státního úřadu (xxxx označovaný xxx xxxx cable Law"). „Regulační orgán“) a jakéhokoli jiného úřadu, které se vztahují na provádění Klin- ického hodnocení nebo na činnosti zamýšlené touto Smlouvou (xxxx označo- vané xxx xxxx „Příslušné právní předpisy”).
Study Standards. Institution and Investigator shall perform the Study in accordance with (i) the terms and conditions of this iv) generally accepted standards of good clinical practice; (v) the International Council on Harmonization of Technical Requirements of Pharmaceuticals for Human Use Guideline for Good Clinical Practice (“ICH-GCP”); and (vi) all national and international laws, ordinances, rules ( e.g. relevant legislation, SÚKL's requirements), and regulations of any governmental authority ("Regulatory Authority") and any other authority that apply to the conduct of the Study or the activities contemplated hereunder ("Applicable Law"). 1.1
Study Standards. In performing the Supplemental Review, PNM will use appropriate electric utility practices to determine whether the GF can be interconnected to the EPS safely and reliably. Each Party will perform its obligations as set forth in this Agreement in a manner that reflects best practices in the electric industry and that are consistent with regional practices, applicable laws and regulations, and the organizational nature of each Party. All of the terms and provisions, to the extent practicable, shall be consistent with the provisions of Rule 568.
Study Standards. The study procedure will use Good Utility Practice and the engineering and operating principles, standards, guidelines and criteria of the Transmission Provider, the Regional Reliability Council of which the Transmission Provider is a member, any entity of which the Transmission Provider is a member and is approved by the Commission to promulgate or apply regional or national planning and reliability standards (such as a regional transmission group, RTG), NERC or any similar organization that may exist in the future of which the Transmission Provider is then a member. In all cases, system addition(s) to the electric supply facilities shall maintain or improve the Transmission Provider’s transmission system operation, reliability and transfer capability.
